Myriad Genetics, Inc.

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-16 pm EST			5-day change	1st Jan Change
6.880 ^USD	-1.57%		-6.39%	-49.82%

Nov. 26	Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	MT
Nov. 25	Myriad Genetics Collaborates With Clairity, MagView to Roll Out AI Platform for Breast Cancer Risk Assessment	MT

(MYGN) Myriad Genetics Expects Fiscal Year 2025 Revenue Range $840M - $860M

Published on 01/15/2025 at 08:31 am EST - Modified on 01/15/2025 at 08:32 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Myriad Genetics, Inc.

Nov. 26	Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	MT
Nov. 25	Myriad Genetics Collaborates With Clairity, MagView to Roll Out AI Platform for Breast Cancer Risk Assessment	MT
Nov. 25	Clairity, Myriad Genetics, Inc. and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health	CI
Nov. 10	Myriad Genetics Expands Cancer Test With Additional Actionable Genes From NCCN Guidelines	MT
Nov. 10	Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk®? Hereditary Cancer Test to Support Evolving Clinical Needs	CI
Nov. 06	Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference	CI
Nov. 04	UBS Adjusts Myriad Genetics Price Target to $8 From $6, Maintains Neutral Rating	MT
Nov. 03	Myriad Genetics, Inc., Q3 2025 Earnings Call, Nov 03, 2025
Nov. 03	Myriad Genetics Q3 revenue beats on volume growth in hereditary cancer testing	RE
Nov. 03	Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full-Year 2025	CI
Nov. 03	Myriad Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Oct. 31	Myriad Genetics, Inc. Announces A Post-Hoc Analysis of the Precision Medicine in Mental Health Care Study	CI
Oct. 30	Neogen® Corporation Announces the Appointment of Bryan Riggsbee as Its Senior Vice President, Effective November 3, 2025	CI
Oct. 30	Neogen® Corporation Announces the Appointment of Bryan Riggsbee as Chief Financial Officer, Effective November 3, 2025	CI
Oct. 15	Kringle Pharma Establishes US Subsidiary to Accelerate Spinal Cord Injury Program	MT
Oct. 14	Myriad Genetics, Inc. Adds F8, FXN Genes to Foresight Universal Plus Panel	CI
Oct. 03	Myriad Genetics, Inc. Announces Executive Changes, Effective October 24, 2025	CI
Oct. 01	Revance Appoints Scott Leffler as Chief Financial Officer, Effective October 1, 2025	CI
Sep. 23	Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy	CI
Sep. 23	Myriad Genetics, Sophia Genetics Partner on Global Liquid Biopsy Test for Pharma Trials	MT
Sep. 10	Myriad Genetics, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-10-2025 07:45 AM
Sep. 04	Myriad Genetics, Inc. Announces Precise MRD Clinical Data Published in The Lancet Oncology	CI
Sep. 03	New meta-analysis demonstrates that access to the GeneSight test can significantly improve response and remission rates for patients with depression	RE
Sep. 03	Myriad Genetics, Inc. Announces the Publication of New Meta- Analysis of Six Prospective Controlled Studies	CI
Aug. 20	Angle teams up with Myriad Genetics on cancer patient blood testing	AN

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Employees

2,700

Sector

Medical Equipment, Supplies & Distribution

Calendar

Jan. 14 - J.P. Morgan Healthcare Conference

More about the company